


Amended Claims

Claims 1-7 (canceled).

8. (currently amended) A compound; an isomer of the compound, enantiomer of the compound, tautomer of the compound, racemate of the compound, or polymorph of the compound; or a pharmaceutically-acceptable salt of the compound, isomer, enantiomer, tautomer, or racemate, wherein: [[of]]

the compound corresponds in structure to Formula I:



wherein

Z₁ is selected from the group consisting of CH₂, O, CH₂O, NH, S, SO, CH(OH), and SO₂;

Z₂ is a 1-5 carbon linker optionally containing one or more ~~heteroatom~~ heteroatoms selected from the group consisting of O, S, and N; [[or]]

Z₁-Z₂ optionally further contains ~~contain~~ a carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, or acyl; ~~group; wherein~~

the carbon and nitrogen atoms of Z₁-Z₂ are optionally substituted by a substituent selected from the group consisting of alkyl, alkoxy, ~~thioalkyl~~ alkylthio, alkylsulfone, aryl, alkoxyalkyl, alkylamino, heteroaryl, hydroxyl, alkenyl, alkynyl, carboxyalkyl, halogen, haloalkyl, and acylamino;

each n is ~~an integer~~ selected from the group consisting of zero, 1, and 2;

R^c is selected from the group consisting of hydrogen, alkyl, halogen, hydroxyl, nitro, alkoxy, amino, haloalkyl, aryl, heteroaryl, alkoxyalkyl, aminoalkyl, hydroxyalkyl, ~~thioalkyl~~ alkylthio, alkylamino, arylamino, alkylsulfonylamino, acyl, acylamino, sulfonyl, sulfonamide, allyl, alkenyl, methylenedioxy, ethylenedioxy, alkynyl, alkynylalkyl, carboxy, alkoxycarbonyl, carboxamido, cyano, and $-(CH_2)_n-COR_1$; ~~wherein n is an integer selected from the group consisting of zero, 1 and 2, and~~

R is selected from the group consisting of hydroxyl, alkoxy, alkyl, and amino;


X is selected from the group consisting of $[-O-]$, O, CO, SO_2 , NR^m , and $(CHR^p)_n$;

wherein


R^p and R^m are H or alkyl; ~~n is an integer selected from the group consisting of zero, 1 and 2; R^b is X_3-R^h wherein~~













X_3 is selected from the group consisting of O, S, and NR^j ; ~~wherein~~













R^h and R^j are independently selected from the group consisting of H, alkyl, acyl, aryl, aralkyl, and alkoxyalkyl; and



























A¹ is selected from the group consisting of:











































































4


















































and pharmaceutically acceptable salts, isomers, enantiomers, tautomers, racemates or polymorphs thereof, wherein m is an integer selected from the group consisting of 1 and 2; B¹ is selected from the group consisting of CH₂, O, CO, S, CF₂, SO₂, and NR⁶; B² is selected from the group consisting of N and CH; B³ is selected from the group consisting of N and CH; B⁴ is selected from the group consisting of NH, O and S; B⁵ is selected from the group consisting of NH, O and S; B⁶ is selected from the group consisting of N and CH; B⁷ is

~~selected from the group consisting of CH₃, O, CO, S, CF₃, SO₂, and NR^a; R⁷⁹ is selected from the group consisting of OR^a, OH, H and Me; R⁸⁰ is selected from the group consisting of H and Me; R⁸¹ is selected from the group consisting of OR^a, OH and Me; X⁷ is selected from the group consisting of O, S, NR^a, SO₂, and CF₃; X⁸ is selected from the group consisting of CH₃, O, S, NR^a, SO₂, and CONR^a; and R^a is selected from the group consisting of H, alkyl and amino.~~

9. (currently amended) A compound, isomer, enantiomer, tautomer, racemate, polymorph, or salt according to claim 8, wherein said compound is 1,2,3,4-tetrahydro-1-oxo-[6-[3-(2-tetrahydropyrimidinyl)amino]-propoxy]-2-isoquinolineacetic acid, ~~and pharmaceutically acceptable salts, isomers, enantiomers, tautomers, racemates or polymorphs thereof.~~

10. (currently amended) A pharmaceutical composition, wherein the composition comprises: comprising a therapeutically effective amount of
a compound, isomer, enantiomer, tautomer, racemate, polymorph, or salt of claim 8
in an amount that is effective to inhibit or antagonize $\alpha_v\beta_3$ or $\alpha_v\beta_5$; and
a pharmaceutically acceptable carrier.

11. (currently amended) A method for treating a condition mediated by the $\alpha_v\beta_3$ integrin in a mammal, wherein:

the condition is selected from the group consisting of tumor metastasis, tumor growth, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy, and arthritis; ~~and in a mammal in need of such treatment comprising~~

the method comprises administering an effective $\alpha_v\beta_3$ inhibiting amount of a compound, isomer, enantiomer, tautomer, racemate, polymorph, or salt of claim 8.

Claim 12. (canceled).

13. (currently amended) A method for treating a condition mediated by the $\alpha_v\beta_3$ integrin in a mammal, wherein:

the condition is selected from the group consisting of tumor metastasis, tumor growth, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy, and arthritis; ~~and in a mammal in need of such treatment comprising~~

the method comprises administering an effective $\alpha_v\beta_3$ inhibiting amount of a compound, isomer, enantiomer, tautomer, racemate, polymorph, or salt of claim 8.

Claim 14. (canceled).

15. (currently amended) A method of treating neoplasia in a patient in need thereof, wherein the method comprises ~~comprising~~ administering a compound, isomer, enantiomer, tautomer, racemate, polymorph, or salt of claim 8 in combination with a chemotherapeutic agent.

Claim 16. (canceled).